NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Abou-Setta AM, Mousavi SS, Spooner C, et al. First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2012 Aug. (Comparative Effectiveness Reviews, No. 63.)

Cover of First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness

First-Generation Versus Second-Generation Antipsychotics in Adults: Comparative Effectiveness [Internet].

Show details

References

1.
Meltzer HY, Huang M. In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res. 2008;172:177–97. [PubMed: 18772033]
2.
Lopez-Gil X, Artigas F, Adell A. Unraveling monoamine receptors involved in the action of typical and atypical antipsychotics on glutamatergic and serotonergic transmission in prefrontal cortex. Curr Pharm Des. 2010;16(5):502–15. [PubMed: 19909228]
3.
Wang CC, Farley JF. Patterns and predictors of antipsychotic medication use among the U.S. population: Findings from the Medical Expenditure Panel Survey. Res Social Adm Pharm. 2009 [PubMed: 21272525]
4.
Alexander GC, Gallagher SA, Mascola A, et al. Increasing off-label use of antipsychotic medications in the United States, 1995–2008. Pharmacoepidemiol Drug Saf. 2011;20(2):177–84. [PMC free article: PMC3069498] [PubMed: 21254289]
5.
Ascher-Svanum H, Nyhuis AW, Stauffer V, et al. Reasons for discontinuation and continuation of antipsychotics in the treatment of schizophrenia from patient and clinician perspectives. Curr Med Res Opin. 2010;26(10):2403–10. [PubMed: 20812791]
6.
Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41. [PubMed: 19058842]
7.
McDonagh M, Peterson K, Carson S, et al. Drug Class Reviews. Portland (OR): Oregon Health & Science University; Jul, 2010. Drug Class Review: Atypical Antipsychotic Drugs: Final Update 3 Report. [Internet] 2010. [PubMed: 21348048]
8.
Maglione M, Maher AR, Hu J, et al. Off-Label Use of Atypical Antipsychotics: An Update. Rockville (MD): Agency for Healthcare Research and Quality (US); Sep, 2011. [Internet] Report No: 11-EHC087-EF AHRQ Comparative Effectiveness Reviews 2011. [PubMed: 22132426]
9.
Seida JC, Schouten R, Mousavi SS, et al. First- and Second-Generation Antipsychotics for Children and Young Adults, Comparative Effectiveness Review No 39. Rockville, MD: Agency for Healthcare Research and Quality; 2011. (Prepared by the University of Alberta Evidence-based Practice Center under Contract No 290-2007-10021) AHRQ Publication No 11-EHC077.
10.
American Psychiatry Association. Diagnostic and Statistical Manual of Mental Disorders Fourth Edition, Text Revision ed. Washington, D.C: American Psychiatric Association; 2000.
11.
Bhugra D. The global prevalence of schizophrenia. PLoS Med. 2005;2(5):e151. [PMC free article: PMC1140960] [PubMed: 15916460]
12.
American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. 2nd ed. Arlington (VA): American Psychiatric Association; 2004.
13.
Carlsson A. Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry. 1978;135(2):165–73. [PubMed: 23684]
14.
Nikam SS, Awasthi AK. Evolution of schizophrenia drugs: a focus on dopaminergic systems. Curr Opin Investig Drugs. 2008;9(1):37–46. [PubMed: 18183530]
15.
Campbell M, Young PI, Bateman DN, et al. The use of atypical antipsychotics in the management of schizophrenia. Br J Clin Pharmacol. 1999;47(1):13–22. [PMC free article: PMC2014208] [PubMed: 10073734]
16.
Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs. 2008;68(16):2269–92. [PubMed: 18973393]
17.
Kane J. Commentary: consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):223–4. [PMC free article: PMC2632202] [PubMed: 16221996]
18.
Miyamoto S, Duncan GE, Mailman RB, et al. Developing novel antipsychotic drugs: strategies and goals. Curr Opin CPNS Invest Drugs. 2000;2:25–39.
19.
Dawkins K, Lieberman JA, Lebowitz BD, et al. Antipsychotics: Past and Future: National Institute of Mental Health Division of Services and Intervention Research Workshop, July 14, 1998. Schizophr Bull. 1999;25(2):395–405. [PubMed: 10416740]
20.
Murphy BP, Chung YC, Park TW, et al. Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophr Res. 2006;88(1–3):5–25. [PubMed: 16930948]
21.
Jones PB, Barnes TR, Davies L, et al. Randomized controlled trial of the effect on Quality of Life of second vs. first generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1) Arch Gen Psychiatry. 2006;63(10):1079–87. [PubMed: 17015810]
22.
Lewis SW, Barnes TR, Davies L, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull. 2006;32(4):715–23. [PMC free article: PMC2632262] [PubMed: 16540702]
23.
Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;(12):1209–23. [PubMed: 16172203]
24.
McEvoy JP, Lieberman JA, Stroup TS, et al. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry. 2006;163(4):600–10. [PubMed: 16585434]
25.
Lieberman JA, Stroup TS. The NIMH-CATIE Schizophrenia Study: what did we learn? Am J Psychiatry. 2011;168(8):770–5. [PubMed: 21813492]
26.
Practice guideline for the treatment of patients with bipolar disorder (revision) Am J Psychiatry. 2002;159(4 Suppl):1–50. [PubMed: 11958165]
27.
Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration; 2008.
28.
Eden J, Levit L, Berg A, Morton S, editors. Institute of Medicine of the National Academies. The National Academies Press; 2011. Finding what works in health care: standards for systematic reviews/Committee on Standards for Systematic Reviews of Comparative Effectiveness Research, Board on Health Care Services, Institute of Medicine of the National Academies.
29.
Berlin JA. Does blinding of readers affect the results of meta-analyses? University of Pennsylvania Meta-analysis Blinding Study Group. Lancet. 1997;350(9072):185–6. [PubMed: 9250191]
30.
Wells G, Shea B, O’Connell D, Peterson J, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. Dept of Epidemiology & Community Medicine, University of Ottawa; Canada: 2009. Available from: URL: http://www​.ohri.ca/programs​/clinical_epidemiology/oxford.htm.
31.
Tran-Johnson TK, Sack DA, Marcus RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(1):111–9. [PubMed: 17284138]
32.
Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187:235–42. [PubMed: 16135860]
33.
Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo-and haloperidol-controlled study. Br J Psychiatry. 2009;194(1):40–8. [PubMed: 19118324]
34.
Vickers AJ. The use of percentage change from baseline as an outcome in a controlled trial is statistically inefficient: a simulation study. BMC Med Res Methodol. 2001;1:6. [PMC free article: PMC34605] [PubMed: 11459516]
35.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88. [PubMed: 3802833]
36.
Lau J, Ioannidis JP, Schmid CH. Summing up evidence: one answer is not always enough. Lancet. 1998;351(9096):123–7. [PubMed: 9439507]
37.
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. [PubMed: 12111919]
38.
Hayashino Y, Noguchi Y, Fukui T. Systematic evaluation and comparison of statistical tests for publication bias. J Epidemiol. 2005;15(6):235–43. [PubMed: 16276033]
39.
Owens DK, Lohr KN, Atkins D, et al. Grading the strength of a body of evidence when comparing medical interventions. Agency for Healthcare Research and Quality and the Effective Health Care Program. J Clin Epidemiol. 2009 [PubMed: 19595577]
40.
Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336(7650):924–6. [PMC free article: PMC2335261] [PubMed: 18436948]
41.
Gartlehner G, Hansen RA, Nissman D, Lohr KN, et al. Criteria for distinguishing effectiveness from efficacy trials in systematic reviews: Technical Review 12. Rockville, MD: Agency for Healthcare Research and Quality; Apr, 2006. (Prepared by the RTI-International-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) AHRQ Publication No. 06-0046. [PubMed: 20734508]
42.
Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. [PMC free article: PMC2707599] [PubMed: 19621072]
43.
Altamura AC, Velona I, Curreli R, et al. Is olanzapine better than haloperidol in resistant schizophrenia? A double-blind study in partial responders. Int J Psychiatr Clin Pract. 2002;6(2):107–11. [PubMed: 24931937]
44.
Andrezina R, Josiassen RC, Marcus RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl) 2006;188(3):281–92. [PubMed: 16953381]
45.
Apiquian R, Fresan A, Munoz-Delgado J, et al. Variations of rest, activity rhythm and sleep, wake in schizophrenic patients versus healthy subjects: an actigraphic comparative study. Biol Rhythm Res. 2008;39(1):69–78.
46.
Arvanitis LA, Miller BG. Multiple fixed doses of “Seroquel” (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry. 1997;42(4):233–46. [PubMed: 9270900]
47.
Atmaca M, Kuloglu M, Tezcan E, et al. Quetiapine is not associated with increase in prolactin secretion in contrast to haloperidol. Arch Med Res. 2002;33(6):562–5. [PubMed: 12505103]
48.
Barbini B, Scherillo P, Benedetti F, et al. Response to clozapine in acute mania is more rapid than that of chlorpromazine. Int Clin Psychopharmacol. 1997;12(2):109–12. [PubMed: 9219046]
49.
Beasley CM, Tollefson G, Tran P, et al. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacol. 1996;14(2):111–23. [PubMed: 8822534]
50.
Beasley CM, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol. 1997;7(2):125–37. [PubMed: 9169300]
51.
Bernardo M, Parellada E, Lomena F, et al. Double-blind olanzapine vs. haloperidol D2 dopamine receptor blockade in schizophrenic patients: a baseline-endpoint. Psychiatry Res. 2001;107(2):87–97. [PubMed: 11530275]
52.
Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16(1):38–44. [PubMed: 8834417]
53.
Borison RL, Pathiraja AP, Diamond BI, et al. Risperidone: clinical safety and efficacy in schizophrenia. Psychopharmacol Bull. 1992;28(2):213–8. [PubMed: 1381102]
54.
Boulay LJ, Labelle A, Bourget D, et al. Dissociating medication effects from learning and practice effects in a neurocognitive study of schizophrenia: olanzapine versus haloperidol. Cogn Neuropsych. 2007;12(4):322–38. [PubMed: 17558641]
55.
Breier A, Buchanan RW, Kirkpatrick B, et al. Effects of clozapine on positive and negative symptoms in outpatients with schizophrenia. Am J Psychiatry. 1994;151(1):20–6. [PubMed: 8267129]
56.
Breier A, Meehan K, Birkett M, et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Archives of General Psychiatry. 2002;59(5):441–8. [PubMed: 11982448]
57.
Brook S, Walden J, Benattia I, et al. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl) 2005;178(4):514–23. [PubMed: 15650846]
58.
Buchanan RW, Ball MP, Weiner E, et al. Olanzapine treatment of residual positive and negative symptoms. Am J Psychiatry. 2005;(1):124–9. [PubMed: 15625210]
59.
Cavallaro R, Mistretta P, Cocchi F, et al. Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia. Hum Psychopharmacol. 2001;16(6):439–48. [PubMed: 12404552]
60.
Ceskova E, Svestka J. Double-blind comparison of risperidone and haloperidol in schizophrenic and schizoaffective psychoses. Pharmacopsychiatry. 1993;26(4):121–4. [PubMed: 7694306]
61.
Chouinard G, Jones B, Remington G, et al. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J Clin Psychopharmacol. 1993;13(1):25–40. [PubMed: 7683702]
62.
Citrome L, Volavka J, Czobor P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr Serv. 2001;52(11):1510–4. [PubMed: 11684748]
63.
Claghorn J, Honigfeld G, Abuzzahab FS Sr., et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol. 1987;7(6):377–84. [PubMed: 3323261]
64.
Claus A, Bollen J, De CH, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study. Acta Psychiatr Scand. 1992;85(4):295–305. [PubMed: 1375801]
65.
Glick ID, Marder SR. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder. J Clin Psychiatry. 2005;66(5):638–41. [PubMed: 15889952]
66.
Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry. 1998;(7):914–20. [PubMed: 9659857]
67.
Conley RR, Kelly DL, Nelson MW, et al. Risperidone, quetiapine, and fluphenazine in the treatment of patients with therapy-refractory schizophrenia. Clin Neuropharmacol. 2005;28(4):163–8. [PubMed: 16062094]
68.
Copolov DL, Link CG, Kowalcyk B. A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636,‘Seroquel’) and haloperidol in schizophrenia. Psychol Med. 2000;30(1):95–105. [PubMed: 10722180]
69.
Corripio I, Catafau AM, Perez V, et al. Striatal dopaminergic D2 receptor occupancy and clinical efficacy in psychosis exacerbation: a 123I–IBZM study with ziprasidone and haloperidol. Prog Neuropsychopharmacol Biol Psychiatry. 2005;29(1):91–6. [PubMed: 15610950]
70.
Covington L, Cola PA. Clozapine vs. Haloperidol: antipsychotic effects on sexual function in schizophrenia. Sex Disabil. 2000;18(1):41–8.
71.
Crespo-Facorro B, Perez-Iglesias R, Ramirez-Bonilla M, et al. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry. 2006;67(10):1511–21. [PubMed: 17107241]
72.
Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. New Engl J Med. 2002;346(1):16–22. [PubMed: 11777998]
73.
McCue RE, Waheed R. Comparative effectiveness of second-generation antipsychotics and haloperidol in acute schizophrenia. Br J Psychiatry. 2006;40 [PubMed: 17077434]
74.
Daniel DG, Currier GW, Zimbroff DL, et al. Efficacy and safety of oral aripiprazole compared with haloperidol in patients transitioning from acute treatment with intramuscular formulations. J Psychiatr Pract. 2007;13(3):170–7. [PubMed: 17522560]
75.
Davidson M, Galderisi S, Weiser M, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST) Am J Psychiatry. 2009;166(6):675–82. [PubMed: 19369319]
76.
De Oliveira IR, Elkis H, Gattaz WF, et al. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. CNS Spectr. 2009;14(2):93–102. [PubMed: 19238124]
77.
De Sena EP, Santos-Jesus R, Miranda-Scippa A, et al. Relapse in patients with schizophrenia: a comparison between risperidone and haloperidol. Rev Bras Psiquiatr. 2003;25(4):220–3. [PubMed: 15328547]
78.
De Haan L, Van BM, Lavalaye J, et al. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry. 2003;160(2):303–9. [PubMed: 12562577]
79.
Emsley RA, Raniwalla J. A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol. 2000;15(3):121–31. [PubMed: 10870870]
80.
Emsley R, Turner HJ, Schronen J, et al. Effects of quetiapine and haloperidol on body mass index and glycaemic control: a long-term, randomized, controlled trial. Int J Neuropsychopharmacol. 2005;8(2):175–82. [PubMed: 15737251]
81.
Emsley RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Schizophr Bull. 1999;25(4):721–9. [PubMed: 10667742]
82.
Fakra E, Khalfa S, Da FD, et al. Effect of risperidone versus haloperidol on emotional responding in schizophrenic patients. Psychopharmacology (Berl) 2008;200(2):261–72. [PubMed: 18575849]
83.
Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18(4):296–304. [PubMed: 9690695]
84.
Goldman MB, Hussain N. Absence of effect of olanzapine on primary polydipsia: results of a double-blind, randomized study. J Clin Psychopharmacol. 2004;24(6):678–80. [PubMed: 15538138]
85.
Heck AH, Haffmans PM, de GI, et al. Risperidone versus haloperidol in psychotic patients with disturbing neuroleptic-induced extrapyramidal symptoms: a double-blind, multi-center trial. Schizophr Res. 2000;46(2–3):97–105. [PubMed: 11120421]
86.
Hirsch SR, Kissling W, Bauml J, et al. A 28-week comparison of ziprasidone and haloperidol in outpatients with stable schizophrenia. J Clin Psychiatry. 2002;63(6):516–23. [PubMed: 12088164]
87.
Hong CJ, Chen JY, Chiu HJ, et al. A double-blind comparative study of clozapine versus chlorpromazine on Chinese patients with treatment-refractory schizophrenia. Int Clin Psychopharmacol. 1997;12(3):123–30. [PubMed: 9248867]
88.
Ishigooka J, Inada T, Miura S. Olanzapine versus haloperidol in the treatment of patients with chronic schizophrenia: results of the Japan multicenter, double-blind olanzapine trial. Psychiatry Clin Neurosci. 2001;55(4):403–14. [PubMed: 11442893]
89.
Jakovljevic M. Olanzapine versus fluphenazine in the acute (6-week) treatment of schizophrenia. Psychiatr Danub. 1999;(1–2):3–11.
90.
Janicak PG, Keck PE Jr, Davis JM, et al. A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder. J Clin Psychopharmacol. 2001;21(4):360–8. [PubMed: 11476119]
91.
Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085–97. [PubMed: 18374841]
92.
Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;(9):763–71. [PubMed: 12363115]
93.
Kane JM, McQuade RD, Marcus RN, et al. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry. 2007;(2):213–23. [PubMed: 17335319]
94.
Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry. 1988;45(9):789–96. [PubMed: 3046553]
95.
Kane JM, Marder SR, Schooler NR, et al. Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Archives of General Psychiatry. 2001;58(10):965–72. [PubMed: 11576036]
96.
Kane JM, Khanna S, Rajadhyaksha S, et al. Efficacy and tolerability of ziprasidone in patients with treatment-resistant schizophrenia. Int Clin Psychopharmacol. 2006;21(1):21–8. [PubMed: 16317313]
97.
Kane JM, Cohen M, Zhao J, et al. Efficacy and safety of asenapine in a placebo-and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–15. [PubMed: 20520283]
98.
Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003;(4):325–37. [PubMed: 14609439]
99.
Kee KS, Kern RS, Marshall BD Jr, et al. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res. 1998;31(2–3):159–65. [PubMed: 9689720]
100.
Keefe RS, Poe MP, McEvoy JP, et al. Source monitoring improvement in patients with schizophrenia receiving antipsychotic medications. Psychopharmacology (Berl) 2003;169(3–4):383–9. [PubMed: 12759802]
101.
Keefe RS, Young CA, Rock SL, et al. One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res. 2006;81(1):1–15. [PubMed: 16202565]
102.
Kim SH, Han DH, Joo SY, et al. The effect of dopamine partial agonists on the nicotine dependency in patients with schizophrenia. Hum Psychopharmacol. 2010;25(2):187–90. [PubMed: 20033907]
103.
Klieser E, Strauss WH, Lemmer W. The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia. Acta Psychiatr Scand Suppl. 1994;380:68–73. [PubMed: 8048341]
104.
Kongsakon R, Trinidad-Onate P, Chaudhry HR, et al. Asian outpatients with schizophrenia: a double-blind randomized comparison of quality of life and clinical outcomes for patients treated with olanzapine or haloperidol. J Med Assoc Thailand. 2006;89(8):1157–70. [PubMed: 17048425]
105.
Krakowski MI, Czobor P. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Archives of General Psychiatry. 2006;(6):622–9. [PubMed: 16754835]
106.
Lahti AC, Weiler MA, Holcomb HH, et al. Modulation of limbic circuitry predicts treatment response to antipsychotic medication: a functional imaging study in schizophrenia. Neuropsychopharmacol. 2009;34(13):2675–90. [PMC free article: PMC2784027] [PubMed: 19675535]
107.
Lee SM, Chou YH, Li MH, et al. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(5):1101–7. [PubMed: 17475386]
108.
Lieberman JA, Tollefson G. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry. 2003;(8):1396–404. [PubMed: 12900300]
109.
Lieberman JA, Phillips M, Gu H, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacol. 2003;28(5):995–1003. [PubMed: 12700715]
110.
Lindenmayer JP, Khan A, Iskander A, et al. A randomized controlled trial of olanzapine versus haloperidol in the treatment of primary negative symptoms and neurocognitive deficits in schizophrenia. J Clin Psychiatry. 2007;68(3):368–79. [PubMed: 17388705]
111.
Liu SK, Chen WJ, Chang CJ, et al. Effects of atypical neuroleptics on sustained attention deficits in schizophrenia: a trial of risperidone versus haloperidol. Neuropsychopharmacol. 2000;22(3):311–9. [PubMed: 10693159]
112.
Ljubin T, Milas DZ, Mimica N, et al. A preliminary study of the comparative effects of olanzapine and fluphenazine on cognition in schizophrenic patients. Hum Psychopharmacol. 2000;15(7):513–9. [PubMed: 12404620]
113.
Marder SR, Glynn SM, Wirshing WC, et al. Maintenance treatment of schizophrenia with risperidone or haloperidol: 2-year outcomes. Am J Psychiatry. 2003;(8):1405–12. [PubMed: 12900301]
114.
Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151(6):825–35. [PubMed: 7514366]
115.
McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania: a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15(5):573–85. [PubMed: 16139175]
116.
Miceli JJ, Tensfeldt TG, Shiovitz T, et al. Effects of high-dose ziprasidone and haloperidol on the QTc interval after intramuscular administration: a randomized, single-blind, parallel-group study in patients with schizophrenia or schizoaffective disorder. Clin Ther. 2010;32(3):472–91. [PubMed: 20399985]
117.
Min SK, Rhee CS, Kim CE, et al. Risperidone versus haloperidol in the treatment of chronic schizophrenic patients: a parallel group double-blind comparative trial. Yonsei Med J. 1993;34(2):179–90. [PubMed: 7691017]
118.
Moller HJ, Riedel M, Jager M, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on schizophrenia. Int J Neuropsychopharmacol. 2008;11(7):985–97. [PubMed: 18466670]
119.
Moreno RA, Hanna MM, Tavares SM, et al. A double-blind comparison of the effect of the antipsychotics haloperidol and olanzapine on sleep in mania. Braz J Med Biol Res. 2007;40(3):357–66. [PubMed: 17334533]
120.
Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry. 1995;166(6):712–26. [PubMed: 7545060]
121.
Peuskens J, Link CG. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. Acta Psychiatr Scand. 1997;96(4):265–73. [PubMed: 9350955]
122.
Potkin SG, Weiden PJ, Loebel AD, et al. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol. Int J Neuropsychopharmacol. 2009;12(9):1233–48. [PubMed: 19419595]
123.
Purdon SE, Malla A. Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci. 2001;(2):137–49. [PMC free article: PMC1407745] [PubMed: 11291531]
124.
Purdon SE, Jones BD, Stip E, et al. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psych. 2000;57(3):249–58. [PubMed: 10711911]
125.
Remillard S, Pourcher E, Cohen H. Long-term effects of risperidone versus haloperidol on verbal memory, attention, and symptomatology in schizophrenia. J Int Neuropsychol Soc. 2008;14(1):110–8. [PubMed: 18078537]
126.
Rosenheck R, Cramer J, Xu W, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New Engl J Med. 1997;337(12):809–15. [PubMed: 9295240]
127.
Rosenheck R, Perlick D, Bingham S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;290(20):2693–702. [PubMed: 14645311]
128.
Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159(7):1146–54. [PubMed: 12091192]
129.
Saddichha S, Ameen S, Akhtar S. Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. J Clin Psychopharmacol. 2008;(1):27–31. [PubMed: 18204337]
130.
Sayers SL, Campbell EC, Kondrich J, et al. Cocaine abuse in schizophrenic patients treated with olanzapine versus haloperidol. J Nerv Ment Dis. 2005;193(6):379–86. [PubMed: 15920378]
131.
Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Treatment discontinuation following randomization to open-label olanzapine, risperidone or typical antipsychotics during a one-year treatment for schizophrenia. Clin Schizophr Relat Psychoses. 2008;2(3):226–34.
132.
Schooler N, Rabinowitz J, Davidson M, et al. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005;162(5):947–53. [PubMed: 15863797]
133.
Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol. 1998;21(3):176–80. [PubMed: 9617509]
134.
Sergi MJ, Green MF, Widmark C, et al. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007;164(10):1585–92. [PubMed: 17898351]
135.
Shrivastava A. Comparative study of risperidone and haloperidol on clinical and psychosocial parameters in treatment of schizophrenia: a randomised open trial. Indian J Pscychiatry. 2000;(1):52–6. [PMC free article: PMC2957003] [PubMed: 21407908]
136.
Smelson DA, Ziedonis D, Williams J, et al. The efficacy of olanzapine for decreasing cue-elicited craving in individuals with schizophrenia and cocaine dependence: a preliminary report. J Clin Psychopharmacol. 2006;26(1):9–12. [PubMed: 16415698]
137.
Smith RC, Infante M. The effects of olanzapine on neurocognitive functioning in medication-refractory schizophrenia. Int J Neuropsychopharmacol. 2001;(3):239–50. [PubMed: 11669086]
138.
Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15(1):75–84. [PubMed: 15572276]
139.
Tamrakar SM, Nepal MK, Koirala NR, et al. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia. Kathmandu Univ Med J. 2006;4(2):152–60. [PubMed: 18603890]
140.
Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Archives of General Psychiatry. 2003;60(12):1218–26. [PubMed: 14662554]
141.
Tollefson GD, Beasley CMJ, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry. 1997;154(4):457–65. [PubMed: 9090331]
142.
Alvarez-Jimenez M, Gonzalez-Blanch C, Vazquez-Barquero JL, et al. Attenuation of antipsychotic-induced weight gain with early behavioral intervention in drug-naive first-episode psychosis patients: a randomized controlled trial. J Clin Psychiatry. 2006;67(8):1253–60. [PubMed: 16965204]
143.
Velligan DI, Newcomer J, Pultz J, et al. Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res. 2002;53(3):239–48. [PubMed: 11738537]
144.
Vieta E, Ramey T, Keller D, et al. Ziprasidone in the treatment of acute mania: a 12-week, placebo-controlled, haloperidol-referenced study. J Psychopharmacol. 2010;24(4):547–58. [PubMed: 19074536]
145.
Volavka J, Czobor P, Sheitman B, et al. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry. 2002;159(2):255–62. [PubMed: 11823268]
146.
Wirshing DA, Marshall BD Jr, Green MF, et al. Risperidone in treatment-refractory schizophrenia. Am J Psychiatry. 1999;156(9):1374–9. [PubMed: 10484947]
147.
Wright P, Birkett M, David SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am J Psychiatry. 2001;158(7):1149–51. [PubMed: 11431240]
148.
Wynn JK, Green MF, Sprock J, et al. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007;95(1–3):134–42. [PMC free article: PMC2716219] [PubMed: 17662577]
149.
Yen YC, Lung FW, Chong MY. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(2):285–90. [PubMed: 14751424]
150.
Zhang XY, Zhou DF, Cao LY, et al. Risperidone versus haloperidol in the treatment of acute exacerbations of chronic inpatients with schizophrenia: a randomized double-blind study. Int Clin Psychopharmacol. 2001;16(6):325–30. [PubMed: 11712620]
151.
Lim HK, Kim JJ, Pae CU, et al. Comparison of risperidone orodispersible tablet and intramuscular haloperidol in the treatment of acute psychotic agitation: a randomized open, prospective study. Neuropsychobiology. 2010;62(2):81–6. [PubMed: 20523078]
152.
Chiu E, Burrows G, Stevenson J. Double-blind comparison of clozapine with chlorpromazine in acute schizophrenic illness. Aust NZ J Psychiatry. 1976;10(4):343–7. [PubMed: 798582]
153.
Ekblom B, Haggstrom JE. Clozapine (Leponex) compared with chlorpromazine: a double-blind evaluation of pharmacological and clinical properties. Curr Ther Res Clin Exp. 1974;16(9):945–57. [PubMed: 4154183]
154.
Gelenberg AJ, Doller JC. Clozapine versus chlorpromazine for the treatment of schizophrenia: preliminary results from a double-blind study. J Clin Psychiatry. 1979;40(5):238–40. [PubMed: 374401]
155.
Itoh H, Miura S, Yagi G, et al. Some methodological considerations for the clinical evaluation of neuroleptics: comparative effects of clozapine and haloperidol on schizophrenics. Folia Psychiatr Neurol Jpn. 1977;31(1):17–24. [PubMed: 863344]
156.
Leon CA. Therapeutic effects of clozapine: a 4-year follow-up of a controlled clinical trial. Acta Psychiatr Scand. 1979;59(5):471–80. [PubMed: 380268]
157.
Rinieris P, Christodoulou GN, Souvatzoglou A, et al. Free-thyroxine index in schizophrenic patients before and after neuroleptic treatment. Neuropsychobiology. 1980;6(1):29–33. [PubMed: 6102744]
158.
Shopsin B, Klein H, Aaronsom M, et al. Clozapine, chlorpromazine, and placebo in newly hospitalized, acutely schizophrenic patients: a controlled, double-blind comparison. Archives of General Psychiatry. 1979;36(6):657–64. [PubMed: 375865]
159.
Avasthi A. Olanzapine in the treatment of schizophrenia: an open label comparitive trial from North India. Indian J Pscychiatry. 2001;43(3):257–63. [PMC free article: PMC2956152] [PubMed: 21407865]
160.
Guirguis E, Voineskos G, Gray J. Clozapine (Leponex) vs chlorpromazine (Largatil) in acute schizophrenia: a double-blind controlled study. Curr Ther Res Clin Exp. 1977;21:707–19.
161.
Singer K, Law SK. A double-blind comparison of clozapine (Leponex) and chlorpromazine in schizophrenia of acute symptomatology. J Int Med Res. 1974;2:433–5.
162.
Gaszner P, Makkos Z. Clozapine maintenance therapy in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(3):465–9. [PubMed: 15093952]
163.
Hennessy S, Bilker WB, Knauss JS, et al. Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data. BMJ. 2002;325(7372):1070. [PMC free article: PMC131181] [PubMed: 12424166]
164.
Als-Nielsen B, Gluud LL, Gluud C. Methodological quality and treatment effects in randomised trials: a review of six empirical studies. 112th Cochrane Colloquium; Oct 2–6; Ottawa, Ontario, Canada. 2004.
165.
Pildal J, Hrobjartsson A, Jorgensen KJ, et al. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol. 2007;36(4):847–57. [PubMed: 17517809]
166.
Sismondo S. Pharmaceutical company funding and its consequences: a qualitative systematic review. Contemp Clin Trials. 2008;29(2):109–13. [PubMed: 17919992]
167.
Clark SL, Adkins DE, van den Oord EJ. Analysis of efficacy and side effects in CATIE demonstrates drug response subgroups and potential for personalized medicine. Schizophr Res. 2011;132(2–3):114–20. [PMC free article: PMC3195895] [PubMed: 21872442]
168.
Dawber TR, Meadors GF, Moore FE. Epidemiological approaches to heart disease: the Framingham Study. Am J Public Health Nations Health. 1951;41(3):279–281. [PMC free article: PMC1525365] [PubMed: 14819398]

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (6.5M)

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...